Keytruda (pembrolizumab) is a brand-name IV infusion prescribed to treat many types of cancer, including melanoma and lung cancer. As with other drugs, Keytruda can cause side effects, such as eye ...

Learn about cost, uses, and more of Keytruda (pembrolizumab). It's a prescription drug that treats certain cancers in adults and some children. ... Keytruda may cause mild or serious side effects.

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...

Pembrolizumab is an anticancer drug used to treat certain types of skin, colorectal, bladder and urinary tract cancers, Hodgkin’s disease and specific types of non-small-cell lung cancer.

Median event-free survival was 51.8 months with pembrolizumab and 30.4 without after a median of 38.3 months of follow-up. The team also observed significantly higher rates of major pathologic ...

Pembrolizumab (Keytruda Merck) ... “More studies need to be done regarding the exact pathophysiology and potential side effects of these medications.” For more information: Sources/Disclosures.

Immune-mediated side effects were as expected, he continued. The most common immune side effect was hypothyroidism (15.1%), followed by skin reactions (5.7%) and hyperthyroidism (5.2%). Disclosures ...

FDA has approved perioperative pembrolizumab for ... 1.4% of pembrolizumab subjects in KEYNOTE-689 were not able to have surgery because of side effects. FDA noted pembrolizumab should be ...

The researchers found that people who had pembrolizumab had a longer time before their advanced melanoma got worse and overall they lived longer than the people who had ipilumumab. They also had fewer ...

References: van Rijssen L, Nagtegaal IEC, Ploos van Amstel FK, et al. Safety of accelerated infusion of nivolumab and pembrolizumab. Eur J Cancer.Published online March 21, 2025. doi:10.1016/j ...

Pembrolizumab (Keytruda, Merck Sharp and Dohme) 'in combination with platinum-containing chemotherapy, as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated ...